我們已在上線!
進一步了解
APGN
Apexigen, Inc. Common Stock
APGN
APGN
已下市
APGN已於2023年8月22日下市。
關於: Apexigen Inc is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient's immune system to combat and eradicate cancer.. The company's pipeline of immuno-oncology therapeutic candidates is led by sotigalimab, which is in clinical development, and also includes several preclinical stage immune-oncology programs.
員工: 31
新聞
正面
中性
負面
市場情緒
3個月
正面
0%
中性
0%
負面
0%
我們尚未收到任何關於APGN的最新新聞文章。
價格圖表採用Lightweight Charts™實作